Navigation Links
Cempra to Present Data on Solithromycin's (CEM-101) Potential Against Urogenital Infections and Multidrug-Resistant Pathogens at ECCMID
Date:4/26/2013

CHAPEL HILL, N.C., April 26, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing differentiated antibiotics to meet critical medical needs in the treatment of bacterial infections, today announced that it will present data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Berlin, demonstrating solithromycin's potential to treat urogenital infections and combat challenging pathogens such as enterococci and Legionella pneumophila. All of the presentations will occur on Sunday, April 28.

"Solithromycin, our fourth-generation macrolide, has the right spectrum of activity against a variety of serious gram positive pathogens as well as an emerging favorable safety profile," said Prabha Fernandes , Ph.D., chief executive officer of Cempra.  "The studies to be presented at ECCMID demonstrate the antibiotic's potential against bacterial urethritis as well as against serious pathogens such as enterococcus and Legionella for which therapeutic options are either few or decreasing due to increasing antibiotic resistance.  Solithromycin continues to differentiate itself against other treatments for community-acquired bacterial pneumonia, sexually-transmitted diseases and other serious infections."

Abstract O 274: 11:42-11:54 a.m. CEST: A phase II study to evaluate the efficacy and safety of single-dose oral solithromycin (CEM-101) for treatment of patients with uncomplicated urogenital gonorrhea

E. Hook, III, D. Oldach, B. Jamieson, K. Clark, P. Fernandes

  • Patients with suspected N. gonorrhoeae infections received a single oral 1,200 mg dose of solithromycin
  • Infections were eradicated from all 22 evaluable patients
    '/>"/>

SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cempra, Inc. to Report First Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on May 10, 2012
2. Cempra, Inc. to Present at the Global Technology Community 9th Anti-Infectives Partnering and Deal-Making Conference
3. Cempra, Inc. to Report Second Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on August 8, 2012
4. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
5. Cempra, Inc. Reports Second Quarter 2012 Financial and Operating Results
6. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
7. Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012
8. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
9. Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
10. Grant Awarded to Study Novel Therapies for Muco-Obstructive Diseases Includes Studies on Cempras Solithromycin (CEM-101) in a Cystic Fibrosis Anti-inflammatory Model
11. Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... Remission / Unconfirmed Complete Remission Rate 3.5 Fold Higher ... Compared to Standard ... and MTA: CTIC) announced today that it achieved the primary,efficacy ... for patients with advanced, relapsed aggressive non-Hodgkin,s,lymphoma (NHL) based on ...
... PRINCETON, N.J., Nov. 10 Pharmasset, Inc.,(Nasdaq: VRUS ... ITMN ) today,announced that the first patients have been ... with the hepatitis C virus (HCV).,The trial (run in ... to,investigate the combination of two oral antiviral molecules in ...
Cached Medicine Technology:Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 2Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 3Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint 4Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 2Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 3Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 4Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C 5
(Date:4/23/2014)... scientific director at the National Institute of Arthritis and ... 2014 recipient of the Ross Prize in Molecular Medicine, ... Molecular Medicine . The award will be given on ... in Manhattan, followed by scientific presentations by Dr. O,Shea ... National Institutes of Health. , The award, which includes ...
(Date:4/23/2014)... University researchers have identified an important enzyme pathway that ... too few chromosomes, a condition that has been directly ... associate professor of biochemistry, found that near the end ... enzyme that ensures any breaks in DNA are fully ... genome to daughter cells. This process helps safeguard against ...
(Date:4/23/2014)... that can rapidly screen a large cell population ... that population has been seriously lacking," said Virginia ... Royal Society of Chemistry journal Chemical Science ... coworkers have developed a novel technique that detects ... Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ). ...
(Date:4/23/2014)... April 21, 2014 Five for-profit and non-profit ... $1.25 million in Proof of Concept grants to ... into commercial products, the Life Sciences Discovery Fund ... Entrepreneur Mentoring Program grant to the Washington Biotechnology ... advisory network to train the next generation of ...
(Date:4/23/2014)... as Ritalin, may prevent the depletion of self-control, according ... journal of the Association for Psychological Science. , Self-control ... trying to focus attention on a boring textbook are ... explanation for this difficulty: Exerting self-control for a long ... effectively on subsequent tasks. , "It is as if ...
Breaking Medicine News(10 mins):Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:ADHD drug may help preserve our self-control resources 2
... Will Retire from the Lilly ... Board, ... LLY ) has elected Michael L. Eskew, former,chairman and chief executive officer ... Eskew will stand for election,by the shareholders at the 2008 annual meeting in ...
... Feb. 19 WeissComm Partners,the largest independent ... announced the appointment of Tom Jones as ... Corporation,where he was executive director of communications, ... relations programs for the,company,s growth driver brands. ...
... Nation,s 6th Best Hospital, DENVER, Feb. ... Board: GLOB), an international e-Health, medical,information technology ... has signed an agreement with NewYork-Presbyterian,Hospital (NYP), ... in the,world, to license its SafeTrace Tx(R) ...
... under control, researchers say , , TUESDAY, Feb. 19 (HealthDay ... blood pressure under control, and this may help explain ... pressure. , That,s just one of a series of ... of the journal Hypertension . The issue commemorates ...
... While Cutting Prices for,Existing Drugs, According to a ... Mass., Feb. 19 Decision Resources, Inc., one,of ... on,pharmaceutical and healthcare issues, finds that Japan has ... for 2008 and beyond.,The changes reflect the Japanese ...
... Feb. 19 Arcapita Inc., a leading private,equity investment ... its,affiliates have agreed to sell TLC Health Care Services, ... AMED ), for an enterprise value of,$395 million., ... York, TLC is the,largest privately-held home healthcare provider in ...
Cached Medicine News:Health News:Michael L. Eskew Elected to Lilly Board of Directors 2Health News:WeissComm Partners Names Tom Jones Managing Director to Deepen Global Product Communications Offering 2Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 2Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 3Health News:Global Med Technologies(R), Inc. Adds Internationally Renowned NewYork- Presbyterian Hospital to Client List 4Health News:Hypertension a Health Challenge for Women 2Health News:Hypertension a Health Challenge for Women 3Health News:Japan Backs Away from Making Real Changes to Its Rx Pharma Pricing Mechanism 2Health News:Arcapita to Sell TLC Health Care Services, Inc. for $395 Million 2
... Gore's EXCLUDER AAA Endoprosthesis is an ... invasive treatment option for patients with abdominal ... a durable ePTFE bifurcated graft with an ... both device flexibility and material durability. The ...
... remove a cast from an arm or leg ... are cut or burned by the cast saw ... to remove any cast with confidence. This innovative, ... and burns from the cast saw and can ...
... choice plays an important part in ... particularly where reduced capsule formation, inflammation ... considerations. GORE-TEX Suture, a nonabsorbable, ePTFE ... characteristics sought by a variety of ...
... Patch utilizes advanced fluoropolymer technology, ... penetrating suture and decrease suture ... as 88 percent. This improvement, ... multi-directional strength and low thrombogenicity, ...
Medicine Products: